Skip to main content
. 2022 Feb 21;10(2):339. doi: 10.3390/vaccines10020339

Figure 5.

Figure 5

Face-1 (HLA-E) and Face-2 (HLA-I) expression on the cell surface of adenocarcinoma and diffuse carcinoma. Note high expression of Face-2 identified with MEM-E/02 in the lymph node metastatic cancer cells.